Literature DB >> 10399061

Simian virus 40 infection via MHC class I molecules and caveolae.

L C Norkin1.   

Abstract

MHC class I molecules are a necessary component of the cell surface receptor for simian virus 40 (SV40). After binding to class I molecules, SV40 enters cells via a unique endocytic pathway that involves caveolae, rather than clathrin-coated pits. This pathway is dependent on a transmembrane signal that SV40 transmits from the cell surface. Furthermore, it delivers SV40 to the endoplasmic reticulum, rather than to the endosomal/lysosomal compartment, which is the usual target for endocytic traffic. The glycosphingolipid and cholesterol-enriched plasma membrane domains that contain caveolae are also enriched for class I molecules, relative to whole plasma membrane. Nevertheless, although class I molecules bind SV40, they do not enter with SV40, nor do they enter spontaneously into uninfected SV40 host cells. Instead, they are shed from the cell surface by the activity of a metalloprotease. These results imply the existence of a putative secondary receptor for SV40 that might mediate SV40 entry. It is not yet clear whether class I molecules are active in transmitting the SV40 signal. Monoclonal antibodies against class I molecules also induce a signal in the SV40 host cells. However, the antibody-induced signal is mediated by mitogen-activated protein kinase (MAP kinase), whereas the SV40 signal is independent of MAP kinase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399061     DOI: 10.1111/j.1600-065x.1999.tb01279.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  35 in total

1.  Caveolae are involved in the trafficking of mouse polyomavirus virions and artificial VP1 pseudocapsids toward cell nuclei.

Authors:  Z Richterová; D Liebl; M Horák; Z Palková; J Stokrová; P Hozák; J Korb; J Forstová
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Targeting and imaging signature caveolar molecules in lungs.

Authors:  Kerri A Massey; Jan E Schnitzer
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

3.  Plasmalemmal vesicle associated protein (PV1) modulates SV40 virus infectivity in CV-1 cells.

Authors:  Dan Tse; David A Armstrong; Ariella Oppenheim; Dmitry Kuksin; Leonard Norkin; Radu V Stan
Journal:  Biochem Biophys Res Commun       Date:  2011-07-30       Impact factor: 3.575

4.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

5.  Multiple pathways involved in porcine parvovirus cellular entry and trafficking toward the nucleus.

Authors:  Maude Boisvert; Sandra Fernandes; Peter Tijssen
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

Review 6.  Lipids in the cell: organisation regulates function.

Authors:  Ana L Santos; Giulio Preta
Journal:  Cell Mol Life Sci       Date:  2018-02-09       Impact factor: 9.261

7.  Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis.

Authors:  V Maréchal; M C Prevost; C Petit; E Perret; J M Heard; O Schwartz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection.

Authors:  Che Man Chan; Susanna K P Lau; Patrick C Y Woo; Herman Tse; Bo-Jian Zheng; Ling Chen; Jian-Dong Huang; Kwok-Yung Yuen
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 9.  Co-option of endocytic functions of cellular caveolae by pathogens.

Authors:  J S Shin; S N Abraham
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

10.  In vitro and in vivo functional characterization of gutless recombinant SV40-derived CFTR vectors.

Authors:  C Mueller; M S Strayer; J Sirninger; S Braag; F Branco; J-P Louboutin; T R Flotte; D S Strayer
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.